Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ACIU
stocks logo

ACIU

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
1.24M
+9.15%
-0.157
-2.08%
405.57K
-59.03%
0.000
-100%
45.41M
+3376.69%
0.000
-100%
Estimates Revision
The market is revising Upward the revenue expectations for AC Immune SA (ACIU) for FY2025, with the revenue forecasts being adjusted by 11.01% over the past three months. During the same period, the stock price has changed by 26.32%.
Revenue Estimates for FY2025
Revise Upward
up Image
+11.01%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-8.86%
In Past 3 Month
Stock Price
Go Up
up Image
+26.32%
In Past 3 Month
Wall Street analysts forecast ACIU stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACIU is 10.00 USD with a low forecast of 8.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast ACIU stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACIU is 10.00 USD with a low forecast of 8.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.880
sliders
Low
8.00
Averages
10.00
High
12.00
Current: 2.880
sliders
Low
8.00
Averages
10.00
High
12.00
HC Wainwright & Co.
Andrew Fein
Strong Buy
Reiterates
$16
2025-04-03
Reason
HC Wainwright & Co.
Andrew Fein
Price Target
$16
2025-04-03
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Andrew Fein
Strong Buy
Reiterates
$16
2025-03-14
Reason
HC Wainwright & Co.
Andrew Fein
Price Target
$16
2025-03-14
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for AC Immune SA (ACIU.O) is -5.36, compared to its 5-year average forward P/E of -6.69. For a more detailed relative valuation and DCF analysis to assess AC Immune SA 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-6.69
Current PE
-5.36
Overvalued PE
3.38
Undervalued PE
-16.77

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-11.35
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
20.52
Undervalued EV/EBITDA
-43.23

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
46.16
Current PS
0.00
Overvalued PS
147.50
Undervalued PS
-55.19
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

ACIU News & Events

Events Timeline

(ET)
2025-11-04
07:13:29
AC Immune Cuts Workforce by Approximately 30% After Strategic Assessment
select
2025-11-04
07:12:53
AC Immune projects funding to last until the end of the third quarter of 2027.
select
2025-11-04
07:12:15
AC Immune Announces Q3 Earnings Per Share of CHF 0.16, Up from CHF 0.05 Last Year
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
11-05Benzinga
BTIG Affirms Buy Rating on AC Immune, Keeps $8 Price Target Intact

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.

  • Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, indicating a robust network for sharing market intelligence.

  • Market Winning Tools: Benzinga Pro is designed to equip traders with the tools and information necessary to succeed in the markets daily.

[object Object]
Preview
9.0
10-24Newsfilter
Groundbreaking Study in Nature Communications Reveals Potential of AC Immune's ACI-19626 as a TDP-43 PET Tracer for Precision Medicine

  • TDP-43 PET Tracer Development: AC Immune SA has published preclinical data on ACI-19626, a first-in-class PET tracer for imaging TDP-43 pathology, which is significant for diagnosing neurodegenerative diseases like ALS, FTD, and Alzheimer's.

  • Clinical Trial Progress: ACI-19626 has shown high specificity and sensitivity in detecting TDP-43 aggregates and is currently advancing into a Phase 1 clinical study, with initial results expected in Q4 2025.

  • Potential Impact on Diagnosis and Treatment: The ability to accurately image TDP-43 pathology could enhance differential diagnosis and facilitate earlier therapeutic interventions, potentially transforming the management of neurodegenerative diseases.

  • Company Background: AC Immune is a clinical-stage biopharmaceutical company focused on precision prevention for neurodegenerative diseases, leveraging its proprietary technology platforms to develop innovative therapeutic and diagnostic solutions.

[object Object]
Preview
4.5
09-04Newsfilter
AC Immune Refines Pipeline Strategy and Enhances Operational Efficiency to Extend Cash Reserves

  • Strategic Focus and Workforce Reduction: AC Immune is sharpening its focus on late-stage clinical development for Alzheimer's and Parkinson's diseases, resulting in a 30% workforce reduction to enhance operational efficiencies.

  • Extended Cash Runway: The company has extended its cash resources to support operations until the end of Q3 2027, with CHF 127.1 million available as of June 30, 2025, excluding potential partnership payments.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is AC Immune SA (ACIU) stock price today?

The current price of ACIU is 2.88 USD — it has increased 1.05 % in the last trading day.

arrow icon

What is AC Immune SA (ACIU)'s business?

AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.

arrow icon

What is the price predicton of ACIU Stock?

Wall Street analysts forecast ACIU stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACIU is 10.00 USD with a low forecast of 8.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is AC Immune SA (ACIU)'s revenue for the last quarter?

AC Immune SA revenue for the last quarter amounts to 939.00K USD, decreased -96.32 % YoY.

arrow icon

What is AC Immune SA (ACIU)'s earnings per share (EPS) for the last quarter?

AC Immune SA. EPS for the last quarter amounts to -0.16 USD, decreased -420.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for AC Immune SA (ACIU)'s fundamentals?

The market is revising Upward the revenue expectations for AC Immune SA (ACIU) for FY2025, with the revenue forecasts being adjusted by 11.01% over the past three months. During the same period, the stock price has changed by 26.32%.
arrow icon

How many employees does AC Immune SA (ACIU). have?

AC Immune SA (ACIU) has 133 emplpoyees as of December 05 2025.

arrow icon

What is AC Immune SA (ACIU) market cap?

Today ACIU has the market capitalization of 289.73M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free